Month: August 2021

GREENWICH, Conn., Aug. 02, 2021 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO) announced the appointment of Jason Papastavrou, Ph.D., to its board of directors upon today’s spin-off of the company from XPO Logistics, Inc. (NYSE: XPO). Until the spin-off, Dr. Papastavrou had been a member of the board of directors of XPO. Dr. Papastavrou is the founder and chief investment officer of ARIS Capital Management, LLC. Previously, he was the founder and managing director of the Fund of Hedge Funds Strategies Group of Banc of America Capital Management (BACAP), president of BACAP Alternative Advisors, and a senior portfolio manager with Deutsche Asset Management. Dr. Papastavrou holds three degrees from the Massachusetts Institute of Technology, including a doctorate in electrical engineering and computer science. About GXO LogisticsGXO Logistics,...

NEENAH, WI, Aug. 02, 2021 (GLOBE NEWSWIRE) — Plexus Corp. (NASDAQ: PLXS) announced today that Randy J. Martinez, former President and CEO of MTS Systems Corp. has joined Plexus Corp.’s Board of Directors. Prior to assuming the role of President and CEO at MTS in 2020 from his position as a Director of the company, Mr. Martinez held various leadership positions within the aviation, aerospace & defense and industrials industries. In addition to joining Plexus Corp.’s Board of Directors, Mr. Martinez will continue to serve on the Board of Directors for the National Defense Transportation Association, First Class Air Holdings and ACORN Growth Companies. Dean Foate, Chairman of Plexus’ Board of Directors, commented, “We are excited to welcome Randy to Plexus’ Board of Directors. Randy brings with him a wealth of relevant expertise...

LAS VEGAS, Aug. 02, 2021 (GLOBE NEWSWIRE) — Software Acquisition Group Inc. III (NASDAQ: SWAGU) (the “Company”) announced today that it closed its initial public offering of 20,000,000 units. The offering was priced at $10.00 per unit, resulting in gross proceeds of $200,000,000. The Company granted the underwriters in the initial public offering, a 45-day option to purchase up to 3,000,000 additional units solely to cover over-allotments, if any. The Company’s units are listed on the Nasdaq Capital Market (“Nasdaq”) and commenced trading under the ticker symbol “SWAGU” on July 29, 2021. Each unit consists of one share of the Company’s Class A common stock and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole...

Second Quarter ResultsTotal revenues of $21.5 million, a 146% year-over-year increase Net loss of $(5.8) million, a $3.0 million improvement compared to $(8.8) million in the second quarter of 2020; loss per diluted share of $(2.41); adjusted net loss of $(4.9) million and adjusted loss per diluted share of $(2.04) Adjusted EBITDA of $(1.6) million, a $6.3 million improvement compared to $(7.9) million in the second quarter of 2020 $13.9 million in cash and $6.0 million of total debt as of June 30, 2021HOUSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) — NCS Multistage Holdings, Inc. (NASDAQ: NCSM) (the “Company,” “NCS,” “we” or “us”), a leading provider of highly engineered products and support services that facilitate the optimization of oil and natural gas well completions and field development strategies, today announced its results...

PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Compensation Committee of its Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 93,600 shares of common stock to 58 new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan. Each stock option has an exercise price per share equal to $14.11 per share, Oyster Point’s closing trading price on the grant date, and will vest over four years, with 1/4th of the underlying shares vesting on the first year anniversary of the applicable vesting date and 1/36th of the remaining...

CHARLOTTE, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) — LPL Financial LLC (Nasdaq:LPLA) today announced that the firm has lowered the investment minimum in its Optimum Market Portfolios (OMP) platform, reducing the amount from $10,000 down to $1,000. This change makes it possible for advisors to offer advisory services to a larger range of clients, giving those with lower investable assets access to professionally managed asset allocation models. “As the industry continues to shift from brokerage to advisory, it is important to have advisory opportunities for all types of investors,” said Rob Pettman, LPL executive vice president, Wealth Management Solutions. “Based on advisor feedback, this enhancement in OMP provides an advisory option for those with smaller amounts to invest, with the added benefit of professionally managed portfolios...

Provides Newtek with Deep Level of Credit Risk Management Experience BOCA RATON, Fla., Aug. 02, 2021 (GLOBE NEWSWIRE) — Newtek Business Services Corp., (Nasdaq: NEWT), an internally managed business development company (“BDC”), today announced that Mr. Nicolas Young has joined Newtek Business Services Corp. (“Newtek” or the “Company”) as Chief Risk Officer. Mr. Young comes to Newtek with over 20 years’ experience in credit risk management and mergers and acquisitions, and has held both managerial and executive roles in the banking industry throughout his career. Mr. Young is a career C-level credit officer who, prior to joining Newtek, was Executive Vice President and Chief Credit Officer for IBERIABANK. Earlier in his career, Mr. Young held the role of Executive Vice President and Chief Credit Officer Americas for Banco Sabadell...

BOCA RATON, Fla., Aug. 02, 2021 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, announced today that it will report its financial results for the second quarter ended June 30, 2021 after the close of the U.S. financial markets on Wednesday, August 11, 2021. The Company will host its conference call on Wednesday, August 11, 2021 at 4:30pm ET to discuss its quarterly results and provide a business update. The conference call information is listed below. The call will also be webcast simultaneously on the Investors section of the red violet website at www.redviolet.com. Please login at least 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be required. CONFERENCE CALL & WEBCAST INFORMATIONWHEN: WEDNESDAY, AUGUST 11, 2021 at 4:30pm...

NASHUA, N.H., Aug. 02, 2021 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, and Stacey Stevens, President, will participate in a fireside chat at the Guggenheim MedTech Disruptors Summit, taking place virtually on August 9-10, 2021. Fireside Chat DetailsDate: August 10, 2021Time: 10:00am Eastern Time About iCAD, Inc. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com. Contact:Media Inquiries:Jessica Burns, iCAD   +1-201-423-4492jburns@icadmed.com Investor Relations:Jeremy Feffer, LifeSci Advisors+ 1-212-915-2568jeremy@lifesciadvisors.com

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees. The awards were made on August 2, 2021 under Oncternal’s 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The awards to the two employees consist of options to purchase an aggregate of 216,400 shares of Oncternal common stock. The options have a 10-year term and an exercise price equal to the closing price of Oncternal’s common stock on the date of grant. The options vest over a four-year period, with 25% of the options vesting on the first...